Search

Meet Antonio Almeida, our February Volunteer of the Month

EHA is a Public Benefit Organization under Dutch law.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013

The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.

Read more

Meet Maria-Victoria Mateos, our April Volunteer of the Month

Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.

Read more

Meet Maria-Victoria Mateos, our April Volunteer of the Month

Maria Victoria Mateos currently heads the Scientific Program Committee of the 24th EHA Congress which will be held on June 13-16 in Amsterdam.

Read more

Restrictions

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed.

Read more